The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Open accessAbstract
Objectives To determine the relationship between non-high-density lipoprotein cholesterol (HDL-C) lowering and coronary heart disease (CHD) risk reduction for various lipid-modifying therapies.Background Non-HDL-C is the second lipid target of therapy after low-density lipoprotein cholesterol (LDL-C).Methods Randomized placebo or active-controlled trials were evaluated. The effect of mean non-HDL-C reduction on the relative risk of nonfatal myocardial infarction and CHD death was estimated using Bayesian random-effects meta-analysis models adjusted for study duration. Cochrane's Q was used to test for heterogeneity.Results Inclusion criteria were met by 14 statin (n = 100,827), 7 fibrate (n = 21,647), and 6 niacin (n = 4,445) trials, and 1 trial each of a bile acid sequestrant (n = 3,806), diet (n = 458), and ileal bypass surgery (n = 838). For statins, each 1% decrease in non-HDL-C resulted in an estimated 4.5-year CHD relative risk of 0.99 (95% Bayesian confidence interval: 0.98 to 1.00). The fibrate model did not differ from the statin model (Bayes factor K = 0.49) with no evidence of heterogeneity. The niacin model was moderately different from the statin model (K = 7.43), with heterogeneity among the trials (Q = 11.8, 5 df; p = 0.038). The only niacin monotherapy trial (n = 3,908) had a 1:1 relationship between non-HDL-C and risk reduction. No consistent relationships were apparent for the 5 small trials of niacin in combination. The 95% confidence intervals for the single trials of diet, bile acid sequestrants, and surgery also included the 1:1 relationship.Conclusions Non-HDL-C is an important target of therapy for CHD prevention. Most lipid-modifying drugs used as monotherapy have an approximately 1:1 relationship between percent non-HDL-C lowering and CHD reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this respect, it is relevant that a meta-analysis of the relationship between improvement of the plasma lipoprotein profile and the rate of CV events has demonstrated that non-HDL-C lowering translates into a reduction in risk independent of the mechanisms (statins, resins, diet and ileal bypass) involved.131”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [131]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Like LDLC, non-HDLC is treatable with existing lipid-lowering agents and there is a direct, consistent relationship between the magnitude of non-HDLC lowering and cardiovascular risk reduction observed in meta-analyses and trials with statins and other lipid-lowering agents [56,57].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [56]
In the citing paper
“Non-HDL-C can provide a better risk estimation compared with LDL-C, in particular in HTG combined with diabetes, the MetS, or CKD.This is supported by a recent meta-analysis including 14 statin trials, seven fibrate trials, and six nicotinic acid trials.44”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [44]
In the citing paper
“Non-HDL cholesterol predicts CVD risk similarly to or even better than LDL cholesterol.483”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [483]
In the citing paper
“In this respect, it is relevant that a meta-analysis of the relationship between improvement of the plasma lipoprotein profile and the rate of CV events has demonstrated that non-HDL-C lowering translates into a reduction in risk independent of the mechanisms (statins, resins, diet and ileal bypass) involved. 131”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [131]
In the citing paper
“However, the meta-analysis of Robinson et al . 131 indicates that LDL-C reduction translates into CV benefits, independent of the mechanism involved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [131]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Kass, R. E., & Raftery, A. E. (1995) · Journal of the American Statistical Association · doi:10.1080/01621459.1995.10476572 · Cited by 12,558
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Research works printed but not linked: 1
- Leren, 1966, The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction, Acta Med Scand, 466, 5
Cited by
Sorted by citations
Items 301–365 of 365
ASGR1 - a new target for lowering non-HDL cholesterol
Hassan, M. S., & Wagdy, K. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.14 · Cited by 2
Update Fettstoffwechselstörungen
Parhofer, K. G. (2013) · Der Internist · doi:10.1007/s00108-013-3335-3 · Cited by 2
Rodríguez, Á. D., Cumplido, A. S., Núñez-Cortés, J. M., de Miguel, M. R., & Peña, M. L. O. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.04.003 · Cited by 2
Authors' reply to commentary entitled “EPA and DHA: Distinct yet essential n-3 fatty acids”
Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.006 · Cited by 2
Self-citationSoran, H., Adam, S., Iqbal, Z., & Durrington, P. N. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-050266 · Cited by 1
Importance and Management of Non–High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment
O’Brien, R. C., Santos, L. E. G., Tomlinson, B., Hussein, Z. B., Lim, S., Nawawi, H. M., Ong, H. Y., Silki, S., Soegondo, S., Su, T., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2025.12.024 · Cited by 2
Non-HDL Cholesterol Versus LDL Cholesterol as a CVD Risk Factor in Diabetic Subjects
Saiedullah, M., Begum, S., Hayat, S., Kamahuddin, S., Rahman, M., & Khan, M. N. K. (2014) · Journal of Bangladesh College of Physicians and Surgeons · doi:10.3329/jbcps.v31i4.21004 · Cited by 1
Novel Lipids Targets in the Era of Metabolic Syndrome
Paneni, F., Palano, F., & Testa, M. (2009) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/11316980-000000000-00000 · Cited by 1
Oikonomou, E. K., Siasos, G., & Tousoulis, D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.059 · Cited by 1
How important are triglycerides as risk factors?
D’Addato, S., Palmisano, S., & Borghi, C. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000438 · Cited by 1
Therapie der diabetischen Dyslipidämie
Brandts, J., & Lebherz, C. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0362-7 · Cited by 1
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Cited by 1
Akbar, S., Rashed, R., Malik, Y. R., Ahmad, K. A., Mumtaz, U., Riffat, N., & Shuja, A. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22165609 · Cited by 1
ALÉ, M. C., Echeverría, G., Jugo, A., Villarroel, L. A., Alberto Maiz, G., & Rigotti, A. (2019) · Revista médica de Chile · doi:10.4067/s0034-98872019001101365 · Cited by 1
Rohatgi, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00008-x · Cited by 1
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.015 · Cited by 1
Junaidi, J., Nur, D., Hudson, I. L., & Stojanovski, E. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04835 · Cited by 1
Zhang, L. (2010) · Työväentutkimus Vuosikirja · Cited by 1
Follow your heart: optimal care after a heart attack - a guide for you and your patients
Sivers, F., Begg, A. G., Milne, D., Morrell, J. M., Neely, D., Norton, M., Nuttall, M., Walker, J. M., Ellis, B., Ratcliffe, C., et al. (2009) · British Journal of Cardiology
Cardiovascular screening: which populations, what measures of risk?
Wierzbicki, A. S. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02566.x
Strandberg, A. Y. (2010) · Työväentutkimus Vuosikirja
Identification and Treatment of Women with Familial Hypercholesterolemia
Robinson, J. G. (2012) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-012-0231-7
Self-citationStężenie cholesterolu nie-HDL u nastolatków obciążonych klinicznymi czynnikami ryzyka miażdżycy
Obuchowicz, A. K., Kniażewska, M., Żmudzińska-Kitczak, J., & Jarecka, B. (2014) · Pediatria Polska · doi:10.1016/j.pepo.2014.07.005
Using Apolipoprotein B to Manage Dyslipidemia–Reply–II
Lavie, C. J., Milani, R. V., & O’Keefe, J. H. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0387
Façons d’identifier et de prendre en charge la dyslipidémie athérogène
Bosomworth, N. J. (2013) · Europe PMC (PubMed Central)
Level of Non-high-density-lipoprotein Cholesterol and Its Related Factors in Chinese Han Students
Yl, F., Liang, L., Fu, J., Cx, G., Xiong, F., Liu, G., Luo, F., & Chen, S. (2013)
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Kulovitz, M. G. (2016) · UNM’s Digital Repository (University of New Mexico)
Statin prescribing in Australian and Irish general practice:a qualitative study
Montgomery, B. (2012) · UWA Profiles and Research Repository (University of Western Australia)
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American
Lennie, T. A., Levi, M., Mazzone, T., Pennathur, S., Goldberg, A. C., Howard, W. J., Jacobson, M. Z., Stone, N. J., Ballantyne, C. M., Bittner, V., et al. (2013)
Cardiac Rehabilitation and Secondary Prevention After Acute MI
Leon, A. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6705-2_28
Façons d’identifier et de prendre en charge la dyslipidémie athérogène
Bosomworth, N. J. (2013) · Canadian Family Physician
Forbes, A. J., Grimes, K. L., York, J. M., & Tsu, L. V. (2015) · Chapman University Digital Commons (Chapman University)
Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides
Davidson, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00025-4
Robinson, J. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00063-7
Self-citationCardiovascular consequences of anabolic steroid use
Angell, P. J. (2017) · Liverpool John Moores University · doi:10.24377/ljmu.t.00006126
Riccio, C., Gulizia, M. M., Colivicchi, F., Lenarda, A. D., Musumeci, G., Faggiano, P. M., Abrignani, M. G., Rossini, R., Fattirolli, F., Valente, S., et al. (2017) · PubMed · doi:10.1093/eurheartj/sux021 · Cited by 2
Kovalyova, O., Ащеулова, Т. В., & Кисиленко, К. В. (2017) · Lviv clinical bulletin · doi:10.25040/lkv2017.04.008
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-124740
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2019) · Gefäßmedizin Scan - Zeitschrift für Angiologie Gefäßchirurgie diagnostische und interventionelle Radiologie · doi:10.1055/a-0858-3922
ROLE OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN CEREBROVASCULAR ACCIDENTS
Sechassayana, N. (2019) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2019/452
Yin, L., Li, Y., Mente, A., Rangarajan, S., Ding, L., Hu, B., Yao, C., Wang, Y., Liu, X., Zhao, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-566020/v1
Ouchi, G., Komiya, I., Taira, S., Wakugami, T., & Ohya, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-1037753/v1
Risk factors and pharmacological therapy in patients with vascular disease
Maiolino, G., Rossato, M., & Vettor, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822113-6.00021-8
Dyslipidämien: Aktuelles Lipid-Management
Müller‐Wieland, D., Lehrke, M., Lebherz, C., Schütt, K. S., & Marx, N. (2020) · Deutsches Ärzteblatt · doi:10.3238/persdia.2020.05.15.02
(2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833643b4
Junaidi, J., Nur, D., Hudson, I. L., & Stojanovski, E. (2022) · Computation · doi:10.3390/computation10050071
Fettstoffwechselstörungen: Therapie
Merkel, M. (2016) · Springer eBooks · doi:10.1007/978-3-642-54676-1_170-2
Durrington, P. N., Bashir, B., & Soran, H. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000834
Impact of risk-reducing salpingo-oophorectomy on lipid determinants, HbA1c and CRP
Vermeulen, R. F. M., van Altena, J. L., Gaarenstroom, K. N., van Beurden, M., Kieffer, J. M., Aaronson, N. K., Kenter, G. G., & Korse, C. M. (2023) · Climacteric · doi:10.1080/13697137.2023.2211762
Fletcher‐Sanfeliu, D., Vidal, L., Enríquez, F., Tarrío, R. F., Padrol, D., Hidalgo, I., Velásquez, A. J., Rigo, M., Barril, R., & de Ibarra, J. I. S. (2024) · Cirugía Cardiovascular · doi:10.1016/j.circv.2023.10.002
Yang, X., Li, K., Xu, G., Wen, J., Xiao, H., Chen, L., Yang, C., Chen, Y., Liu, Y., Zhao, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4634989/v1
Yang, X., Li, K., Xu, G., Wen, J., Xiao, H., Chen, L., Yang, C., Chen, Y., Liu, Y., Zhao, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4905958/v1
Kukharchuk, V. V., Ponomarenko, E. A., Lisitsa, A., Romashova, Y. A., Pleshakova, T. O., Yarovaya, E. B., Kutsenko, V. A., Guseva, M. K., Ipatova, O. M., Karpova, E. A., et al. (2025) · Biomeditsinskaya Khimiya · doi:10.18097/pbmcr1619
Davidson, D., & Davidson, M. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3694-2_14
Gupta, B. K., Pandey, R., Thapa¹, N., Neupane¹, B., Bhattarai¹, S., & Risal, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9141505/v1
Epidémiologie des cardiopathies ischémiques du sujet âgé non institutionnalisé-Etude des Trois Cités
Straczek, C. (2011) · theses.fr (ABES) · doi:10.70675/e600664bzdac0z4adez8151zc8d57336be03
Clinical Assessment of Anti-Atherogenic Function of HighDensity Lipoprotein (HDL)
Ma, F. (2018) · theses.fr (ABES) · doi:10.70675/aec01babza8edz47a2zb4d4zc7c3be00b185
Dosage of lipoproteins for risk management according to guidelines
Bonnin, C., Fourgeaud, C., Mahé, G., Ezzaki, K., Gras, M., Himpens, F. X., Jacquet, R., Khider, L., Mirault, T., Poggi, J. N., et al. (2026) · Vascular Diseases · doi:10.1016/j.vasdi.2026.05.001
Sajid, E. U., Azeem, M. H., Fatima, A., Jafri, S. M., Hassan, D., Ibrahim, T., Manjee, K. Z., Ahmed, S. R., Ali, T., Shakeel, R., et al. (2026) · Clinical Cardiology · doi:10.1002/clc.70369
D’Urso, F., & Broccolo, F. (2026) · Applied Sciences · doi:10.3390/app16168007
Siddiqi, A. K., Jacob, J., Khan, M. S., & Kulkarni, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01465-5
Metadata
- Authors
- Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A.
- Affiliations
- University of Iowa (US)
- Emory University (US)
- Corresponding author
- Robinson, Jennifer G.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 53
- Issue
- 4
- Pages
- 316-322
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1996592745
- Cited by
- 368
- References
- 61
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 13 · 2022: 16 · 2021: 16 · 2020: 15 · 2019: 24 · 2018: 21 · 2017: 21 · 2016: 30 · 2015: 24 · 2014: 27 · 2013: 31 · 2012: 33
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-HDL cholesterol, coronary artery disease, lipid-lowering therapy, statins, fibrates, nicotinic acid, bile acid sequestrants, myocardial infarction, coronary heart disease mortality, relative risk
- MeSH terms
- Clofibric Acid, Coronary Disease, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Niacin, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
